Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Myocardial Blood Flow in Asymptomatic High-Risk Type 2 Diabetes
NCT04541797Active, not recruiting
- Sponsor
- The University of Hong Kong
- Start
- Oct 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) and coronary microvascular disease (CMD) (2 arms), sponsored by The University of Hong Kong. Primary endpoints: Difference in myocardial blood flow as measured by stress CMR at 6 months, Cut-off value for maximum upslope ratio to predict >=10% increase in myocardial blood flow at 6 months and 2 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary microvascular disease (CMD)
Beyond the preview
Go deeper on NCT04541797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541797.